Innovation alliance for new cancer treatment solutions

In the Saxon Network for Radionuclide Theranostics (SNRT), BIOTYPE joins forces with seven partners from science and industry to significantly shape progress in nuclear medicine through the evaluation of molecular biomarkers for patient stratification for therapy decisions and the development of new applications.

Radionuclide theranostics offer impressive potential in the diagnosis and treatment of complex diseases such as various types of cancer. Enormous market growth is predicted for these drugs worldwide. The SNRT aims to create a regional entrepreneurial alliance for innovation that will grow into Europe's leading production and business location for radiopharmaceuticals. From November 2023, the network will receive a total of 12 million euros in funding from the Federal Ministry of Education and Research (BMBF) for the next three years.

Thanks to its competencies and its structures, the SNRT is ideally integrated into the "RUBIN" (“Regional entrepreneurial alliances for innovation”) initiative of the German Federal Ministry of Education and Research (BMBF), which provides the funding.

Read more in the HZDR Press release here: https://www.hzdr.de/db/Cms?pOid=70593&pNid=3438

The partners directly involved are:

ROTOP Pharmaka GmbH | CUP Laboratorien Dr. Freitag GmbH | Helmholtz-Zentrum Dresden-Rossendorf (HZDR) | Technische Universität Dresden | BIOTYPE GmbH | qualitype GmbH | VKTA – Strahlenschutz, Analytik und Entsorgung Rossendorf e.V. | Jähne GmbH Für Produktinnovation